Medical Devices

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

CEO Adrian Mendes' major buy-in signals deep confidence as Perimeter Medical AI navigates FDA approval for its game-changing cancer surgery technology.

Beyond a tagline, The Aesthetic Society is expanding to include non-surgeons, a strategic move to set standards and consolidate influence in a booming market.

A newly validated 'longevity protein' is fueling a biotech gold rush, but can companies turn breakthrough science into viable medicine? An inside look.

Regenerative Patch Technologies advances its stem cell therapy for dry AMD, signaling a potential shift from merely slowing blindness to actively improving vision.

A North Carolina hospital is the first to deploy Mako robotics for shoulder surgery, using AI and haptic tech to offer unprecedented surgical accuracy.

An Atlanta clinic's top award highlights a market shift toward minimally invasive fibroid treatment and a crucial fight for health equity in women's care.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?